Fidanacogene Elaparvovec: First Approval

This article summarizes the milestones in the development of fidanacogene elaparvovec leading to this first approval for moderately severe to severe (factor IX activity ≤ 2%) haemophilia B who are negative for neutralizing antibodies to AAVRh74var.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research